Although several PD-1/PD-L1 inhibitors served as second-line treatments for unresectable HCC patients with a median OS of 13.9–15.6 months [35,36,37], they are not suitable for patients with a high tumor burden and a short life expectancy of less than 3 months. The gene discussed is PDCD1; the disease is neoplasm.